Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

(2019) Chad C. Bjorklund et al.   LEUKEMIA

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies

(2018) Parameswaran Hari et al.   Journal of Geriatric Oncology

Structural basis of thalidomide enantiomer binding to cereblon

(2018) Tomoyuki Mori et al.   Scientific Reports

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity

(2017) Yumi Nakayama et al.   JOURNAL OF IMMUNOLOGY

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

(2017) Mary E. Matyskiela et al.   JOURNAL OF MEDICINAL CHEMISTRY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

(2016) Sundar Jagannath et al.   Expert Review of Hematology

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

(2015) C C Bjorklund et al.   Blood Cancer Journal

Peripheral natural killer cell maturation depends on the transcription factor Aiolos

(2014) M. L. Holmes et al.   EMBO JOURNAL

Ikaros Imposes a Barrier to CD8+ T Cell Differentiation by Restricting Autocrine IL-2 Production

(2014) S. O'Brien et al.   JOURNAL OF IMMUNOLOGY

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE